Showing 9101-9110 of 21416 results for "".
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Precision Starts Before Birth: Reimagining Fetal Care Through FcRn Immune Modulation
https://reachmd.com/programs/cme/Precision-Starts-Before-Birth-Reimagining-Fetal-Care-Through-FcRn-Immune-Modulation/37099/Explore FcRn inhibition as a preventive strategy for HDFN and FNAIT, with focus on ongoing trials including AZALEA and FREESIA.Raising the Bar for Hodgkin Lymphoma: Optimizing Immunotherapy in Community Practice
https://reachmd.com/programs/cme/raising-the-bar-for-hodgkin-lymphoma-optimizing-immunotherapy-in-community-practice/56816/This online activity is designed to provide the healthcare team with the latest developments and critical insights into Hodgkin lymphoma treatment. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clIBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
https://reachmd.com/programs/cme/ibd-masterclass-choosing-the-right-ibd-therapy-a-patient-clinician-connection/54374/A case-based discussion of therapy selection, de-escalation, and treat-to-target approaches in inflammatory bowel disease management.Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
https://reachmd.com/programs/cme/hitting-the-target-in-atopic-dermatitis-interdisciplinary-team-training-for-leveraging-il-13-inhibitors-to-address-the-burden-of-disease/54437/On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Kappa Free Light Chain Index in the Diagnosis of Multiple Sclerosis
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/kappa-free-light-chain-index-in-the-diagnosis-of-multiple-sclerosis/54598/Adoption of the kappa free light chain index can enhance diagnostic accuracy and reduce latency in multiple sclerosis diagnosis, complementing MRI and expert assessment in clinical decision-making.Introduction to Alloimmunization During Pregnancy
https://reachmd.com/programs/alloimmune-disorders-pregnancy/introduction-to-alloimmunization-during-pregnancy/13913/Can you successfully identify and treat your patients who may be at risk of alloimmune disorders of pregnancy?Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
https://reachmd.com/programs/cme/navigating-upated-kdigo-clinical-practice-guideline-recommndations-to-maximize-proteinuria-reduction-in-patients-with-igan/26630/Explore updated KDIGO guideline recommendations and clinical strategies to reduce proteinuria in patients with IgA nephropathy.Treatment Intensification in HSPC: From Risk Stratification to Precision Medicine
https://reachmd.com/programs/cme/Treatment-Intensification-in-HSPC-From-Risk-Stratification-to-Precision-Medicine/56689/Explore individualized treatment intensification, molecular profiling, and adverse event management in metastatic hormone-sensitive prostate cancer.